Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Difference in Distribution of Muscle Weakness Between Myasthenia Gravis and the Lambert-Eaton Myasthenic Syndrome
JNNP 73:766-768, Wirtz,P.W.,et al, 2002
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Myasthenic Symptoms in Patients with Mitochondrial Myopathies
Muscle & Nerve 18:1338-1340, LeForestier,N.,et al, 1995
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
The Neurotoxicity of Antibacterial Agents
Ann Int Med 101:92-104, Snavely,S.R.,et al, 1984
Beta-Adrenoreceptor Antagonists & Diplopia
Lancet 2:826-827, Weber,J.C.P., 1982
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Myasthenia Gravis Assoc. with Wasp Sting
JAMA 235:2120, Brumlik,J., 1976
The Eaton-Lambert Syndrome in Ocular Myasthenia Gravis
Arch Neurol 31:183-186, Oh,S.J., 1974